Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by LPL Financial LLC

LPL Financial LLC trimmed its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 76.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 18,929 shares of the company's stock after selling 59,988 shares during the period. LPL Financial LLC's holdings in Ginkgo Bioworks were worth $186,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the business. Forbes J M & Co. LLP boosted its holdings in shares of Ginkgo Bioworks by 461.4% in the fourth quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock valued at $6,891,000 after acquiring an additional 576,732 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in Ginkgo Bioworks during the 4th quarter worth approximately $29,000. SG Americas Securities LLC purchased a new position in shares of Ginkgo Bioworks during the 4th quarter worth approximately $199,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Ginkgo Bioworks by 8.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 233,717 shares of the company's stock valued at $2,295,000 after buying an additional 17,372 shares during the period. Finally, SPX Gestao de Recursos Ltda purchased a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at approximately $491,000. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Stock Performance

NYSE:DNA traded down $0.18 during trading hours on Monday, hitting $6.86. The company's stock had a trading volume of 123,106 shares, compared to its average volume of 1,576,499. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.00 and a 52-week high of $41.20. The business's 50-day moving average is $7.24 and its two-hundred day moving average is $9.14. The company has a market capitalization of $398.17 million, a PE ratio of -0.52 and a beta of 1.34.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.